A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Review of Obinutuzumab (GA101), a Novel Type II Anti-CD20 Monoclonal Antibody, for the Treatment of Patients with B-Cell Malignancies
Authors
Keywords
Antibody-dependent cell-mediated cytotoxicity, B-cell lymphoma, CD20, Chronic lymphocytic leukemia, Glycoengineering, Monoclonal antibody, Non-Hodgkin lymphoma, Obinutuzumab, Oncology, Rituximab
Journal
ADVANCES IN THERAPY
Volume 34, Issue 2, Pages 324-356
Publisher
Springer Nature
Online
2016-12-21
DOI
10.1007/s12325-016-0451-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma
- (2016) Chia-Yen Lu et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The 2016 revision of the World Health Organization classification of lymphoid neoplasms
- (2016) S. H. Swerdlow et al. BLOOD
- New Strategies for the Treatment of Solid Tumors with CAR-T Cells
- (2016) Hao Zhang et al. International Journal of Biological Sciences
- Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma
- (2016) Nicole C. Smits et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial
- (2016) Laurie H Sehn et al. LANCET ONCOLOGY
- Intravital imaging reveals improved Kupffer cell-mediated phagocytosis as a mode of action of glycoengineered anti-CD20 antibodies
- (2016) Capucine L. Grandjean et al. Scientific Reports
- Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) B. Eichhorst et al. ANNALS OF ONCOLOGY
- Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) H. Tilly et al. ANNALS OF ONCOLOGY
- Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions
- (2015) C. L. Freeman et al. BLOOD
- Randomized phase 2 study of obinutuzumab monotherapy in symptomatic, previously untreated chronic lymphocytic leukemia
- (2015) J. C. Byrd et al. BLOOD
- Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial
- (2015) Jennifer R. Brown et al. BLOOD
- Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies
- (2015) T. R. W. Tipton et al. BLOOD
- Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma
- (2015) G. Cartron et al. HAEMATOLOGICA
- Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study
- (2015) Laurie H. Sehn et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study
- (2015) V Goede et al. LEUKEMIA
- Antibody modulation: Limiting the efficacy of therapeutic antibodies
- (2015) Andrew T. Vaughan et al. PHARMACOLOGICAL RESEARCH
- Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies
- (2015) Liping L. Sun et al. Science Translational Medicine
- Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers
- (2015) L Ysebaert et al. Blood Cancer Journal
- A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys
- (2015) Eric J. Smith et al. Scientific Reports
- Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma
- (2015) G. Cartron et al. HAEMATOLOGICA
- Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody
- (2015) Valentin Goede et al. Oncology Research and Treatment
- Lymphoma Immunotherapy: Current Status
- (2015) Roberta Zappasodi et al. Frontiers in Immunology
- Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2014) M. Dreyling et al. ANNALS OF ONCOLOGY
- Inhibitory Fc RIIb and CD20 internalization
- (2014) I. Dransfield BLOOD
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies
- (2014) M. V. Maus et al. BLOOD
- Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study
- (2014) G. Cartron et al. BLOOD
- Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?
- (2014) D. Grimwade et al. BLOOD
- Fc -receptor-mediated trogocytosis impacts mAb-based therapies: historical precedence and recent developments
- (2014) R. P. Taylor et al. BLOOD
- Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA study
- (2014) Charles H Pritchard et al. BMC MUSCULOSKELETAL DISORDERS
- Are We Nearing an Era of Chemotherapy-Free Management of Indolent Lymphoma?
- (2014) E. Bachy et al. CLINICAL CANCER RESEARCH
- New antibody approaches to lymphoma therapy
- (2014) Tejas Suresh et al. Journal of Hematology & Oncology
- Within Peripheral Blood Mononuclear Cells, Antibody-Dependent Cellular Cytotoxicity of Rituximab-Opsonized Daudi cells Is Promoted by NK Cells and Inhibited by Monocytes due to Shaving
- (2014) P. V. Beum et al. JOURNAL OF IMMUNOLOGY
- Translational Medicine in Action: Anti-CD20 Therapy in Lymphoma
- (2014) Sean H. Lim et al. JOURNAL OF IMMUNOLOGY
- KIR/HLA Interactions Negatively Affect Rituximab- but Not GA101 (Obinutuzumab)-Induced Antibody-Dependent Cellular Cytotoxicity
- (2014) G. Terszowski et al. JOURNAL OF IMMUNOLOGY
- Glycoengineering of Therapeutic Antibodies Enhances Monocyte/Macrophage-Mediated Phagocytosis and Cytotoxicity
- (2014) S. Herter et al. JOURNAL OF IMMUNOLOGY
- Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma
- (2014) Shaker Dakhil et al. LEUKEMIA & LYMPHOMA
- Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions
- (2014) Valentin Goede et al. NEW ENGLAND JOURNAL OF MEDICINE
- The use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapy
- (2014) Monica Coughlan et al. CANCER IMAGING
- Prognostic value of PET-CT after first-line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies
- (2014) Judith Trotman et al. Lancet Haematology
- Obinutuzumab (GA101) plus CHOP or FC in relapsed/refractory follicular lymphoma: results of the GAUDI study (BO21000)
- (2013) J. Radford et al. BLOOD
- Inhibitory Fc RIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity
- (2013) A. T. Vaughan et al. BLOOD
- Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience
- (2013) D. Tan et al. BLOOD
- The induction of immunogenic cell death by type II anti-CD20 monoclonal antibodies has mechanistic differences compared with type I rituximab
- (2013) Eleanor J. Cheadle et al. BRITISH JOURNAL OF HAEMATOLOGY
- Obinutuzumab (GA101) in Patients With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: Results From the Phase II GAUGUIN Study
- (2013) Gilles A. Salles et al. JOURNAL OF CLINICAL ONCOLOGY
- Obinutuzumab (GA101) Monotherapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma or Mantle-Cell Lymphoma: Results From the Phase II GAUGUIN Study
- (2013) Franck Andre Morschhauser et al. JOURNAL OF CLINICAL ONCOLOGY
- Recombinant Human IL-15 Trans-Presentation by B Leukemic Cells from Chronic Lymphocytic Leukemia Induces Autologous NK Cell Proliferation Leading to Improved Anti-CD20 Immunotherapy
- (2013) E. Laprevotte et al. JOURNAL OF IMMUNOLOGY
- Comparative Assessment of Clinically Utilized CD20-Directed Antibodies in Chronic Lymphocytic Leukemia Cells Reveals Divergent NK Cell, Monocyte, and Macrophage Properties
- (2013) S. Rafiq et al. JOURNAL OF IMMUNOLOGY
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- (2013) Mathias J Rummel et al. LANCET
- Apoptotic induction by anti-CD20 antibodies in chronic lymphocytic leukemia: comparison of rituximab and obinutuzumab
- (2013) Lina Reslan et al. LEUKEMIA & LYMPHOMA
- GA101 induces NK-cell activation and antibody-dependent cellular cytotoxicity more effectively than rituximab when complement is present
- (2013) Delila J. Kern et al. LEUKEMIA & LYMPHOMA
- Enhanced anti-tumor activity of the glycoengineered type II CD20 antibody obinutuzumab (GA101) in combination with chemotherapy in xenograft models of human lymphoma
- (2013) Frank Herting et al. LEUKEMIA & LYMPHOMA
- Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties
- (2013) Christian Klein et al. mAbs
- Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics
- (2013) Josée Golay et al. mAbs
- Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
- (2013) S. Herter et al. MOLECULAR CANCER THERAPEUTICS
- Treatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapies
- (2013) Mark Chao Cancer Management and Research
- ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL)
- (2012) M. Ghielmini et al. ANNALS OF ONCOLOGY
- Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway
- (2012) J. Honeychurch et al. BLOOD
- Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
- (2012) G. Salles et al. BLOOD
- A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies
- (2012) L. H. Sehn et al. BLOOD
- Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma
- (2012) Michinori Ogura et al. CANCER SCIENCE
- Chemoimmunotherapy with GA101 plus chlorambucil in patients with chronic lymphocytic leukemia and comorbidity: results of the CLL11 (BO21004) safety run-in
- (2012) V Goede et al. LEUKEMIA
- Endogenous IL-8 acts as a CD16 co-activator for natural killer-mediated anti-CD20 B cell depletion in chronic lymphocytic leukemia
- (2012) Emilie Laprevotte et al. LEUKEMIA RESEARCH
- CD40 stimulation sensitizes CLL cells to lysosomal cell death induction by type II anti-CD20 mAb GA101
- (2011) M. Jak et al. BLOOD
- A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies
- (2011) K.-H. Heider et al. BLOOD
- The future of anti-CD20 monoclonal antibodies: are we making progress?
- (2011) W. Alduaij et al. BLOOD
- Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies
- (2011) W. Alduaij et al. BLOOD
- Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies
- (2011) G. Niederfellner et al. BLOOD
- Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy
- (2011) S. H. Lim et al. BLOOD
- Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab
- (2011) L. Bologna et al. JOURNAL OF IMMUNOLOGY
- Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B Cells
- (2011) P. V. Beum et al. JOURNAL OF IMMUNOLOGY
- Preclinical Studies on the Mechanism of Action and the Anti-Lymphoma Activity of the Novel Anti-CD20 Antibody GA101
- (2011) S. Dalle et al. MOLECULAR CANCER THERAPEUTICS
- Possible misinterpretation of the mode of action of therapeutic antibodies in vitro: homotypic adhesion and flow cytometry result in artefactual direct cell death
- (2010) J. Golay et al. BLOOD
- Response: novel lysosomal-dependent cell death following homotypic adhesion occurs within cell aggregates
- (2010) M. S. Cragg et al. BLOOD
- Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity
- (2010) E. Mossner et al. BLOOD
- Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
- (2010) B. Coiffier et al. BLOOD
- Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells
- (2010) Michaela Patz et al. BRITISH JOURNAL OF HAEMATOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
- (2010) Gilles Salles et al. LANCET
- Long-Term Follow-Up of Patients With Newly Diagnosed Follicular Lymphoma in the Prerituximab Era: Effect of Response Quality on Survival—A Study From the Groupe d'Etude des Lymphomes de l'Adulte
- (2009) Emmanuel Bachy et al. JOURNAL OF CLINICAL ONCOLOGY
- Lymphoma in Adolescents and Young Adults
- (2009) Samantha M. Jaglowski et al. SEMINARS IN ONCOLOGY
- Complement and cellular cytotoxicity in antibody therapy of cancer
- (2008) Siao-Yi Wang et al. EXPERT OPINION ON BIOLOGICAL THERAPY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started